Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CARDIO RENAL METABOLIC

CLINICAL

CCC 2024 LUNCH & NETWORKING

HT-1 - CONVERSATIONS IN OBESITY & CVD MANAGEMENT

Thursday, October 24, 2024
12:00 PM – 12:20 PM PT
Room: Theatre 2 (Exhibit Hall)
Networking
Join the conversation as obesity experts Dr. Paul Poirier (cardiologist) and Dr. Akshay Jain (endocrinologist) come together to unpack the link between obesity and CVD, discuss recent milestones in cardiovascular outcomes trials in obesity, and relate how this data may influence the future of obesity care in cardiology.

Learning Objectives:

At the end of this session participants will be able to:
  • recognize obesity as a cardiometabolic disease and the role of cardiologists in obesity care;
  • discuss the impact of recent cardiovascular outcome trials on obesity care in cardiology; and
  • consider clinical implications of reduced cardiovascular risk in individuals living with obesity.
Disclosure(s):
Akshay Jain, MD, FRCPC, FACE, CCD, ECNU, DABOM: Abbott: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bausch Healthcare: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CPD network: Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Diabetes Canada: Speaker/Honoraria (Ongoing); Eisai: Speaker/Honoraria (Ongoing); gsk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Consultant/Advisory Board (Ongoing); MDBriefcase: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); medtronic: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Moderna: Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Partners in Progressive Medical Education: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); PocketPills: Consultant/Advisory Board (Ongoing); roche: Consultant/Advisory Board (Ongoing); Sandoz: Consultant/Advisory Board (Ongoing); sanofi aventis: Speaker/Honoraria (Ongoing); Takeda: Consultant/Advisory Board (Ongoing); Timed Right: Consultant/Advisory Board (Ongoing)